Conference Coverage

VIDEO: Interventions target opioid overprescribing after gynecologic surgery

View on the News

Inpatient opioid needs can guide discharge prescribing

The important and thought provoking reports by Dr. Mark and by Dr. Weston and their associates present innovative ways for clinicians to address the opioid crisis by prescribing fewer narcotics to postsurgical patients when they leave the hospital. Their work suggests that doing this can have little or no negative impact on patient satisfaction with their care. Their findings give us important documentation for prescribing fewer opioid tablets, while still giving patients adequate pain relief.

Dr. Brent Smith

Dr. Brent Smith

Clinicians are often concerned about providing patients with inadequate pain medication following surgery and the possibility that patients will have to request a refill of their opioid prescription. The results from both of these studies indicate that the narcotic needs of patients while they are hospitalized provide an effective way to predict of the amount of pain medication they will need once they are discharged.

Their findings also provide clear documentation that, in current practice, without guidance like this opioids are often overprescribed, not out of negligence but because clinicians are simply not sure what a patient will need once they go home following gynecologic surgery. By reviewing the pain medication a patient needed in hospital we can better estimate what patients will need when they go home, and we can better avoid giving patients more opioid tablets than they will really need.

Brent Smith, MD , is a gynecologic oncologist at Ohio State University, Columbus. He had no disclosures. Dr. Smith made these comments in a video interview.


 

REPORTING FROM SGO 2018


Under the new program, patients requested an opioid refill 14% of the time after laparotomy and 8% of the time after minimally invasive surgery, rates that did not significantly differ from the prior era. Average postoperative pain scores were identical among patients treated under the new dispensing guidelines and those treated during the prior years, and 96% of patients said they were satisfied with the care they received during the new, restricted dispensing period, Dr. Mark reported.

The single-center experience reviewed by Dr. Weston tracked opioid use by 122 women who underwent a minimally invasive hysterectomy at Women and Infants both as inpatients and out to both 1-2 weeks and 4-6 weeks following discharge. The patients were an average age of 61 years, and included 16% who reported chronic pain and 5% with a history of chronic opioid use.

During the inpatient phase, median opioid use was three doses, with 25% of the patients using no opioids. During the first 1-2 weeks following discharge, median opioid use was nine tablets, with 37% of the patients using no opioids. By the 4- to 6-week follow-up (which collected data from 114 of the patients), median opioid use was a cumulative 11 tablets with 67% of the patients reporting no opioid use during the time between their first and second follow-up visit. During the total postdischarge period, 90% of the patients used 30 or fewer opioid tablets.


A multivariate analysis of the findings showed that opioid use while in hospital was the only significant predictor of opioid use after discharge. Age of 65 years or older showed a nonsignificant trend toward less postdischarge opioid use.

Based on these data Dr. Weston and her associates proposed a formula for estimating a patient’s opioid needs at discharge: Gynecologic surgery patients who needed no opioid medication as inpatients could receive 1-5 opioid tablets at discharge, patients who used opioids at or below the median level should receive 10-15 tablets at discharge, and those who used more than the median number of opioid tablets as inpatients should receive 25-30 tablets at discharge. For patients who undergo surgery as outpatients and have no record of pain medication needs, Dr. Weston recommended discharging them with a prescription for 25-30 tablets, possibly reducing this to 10-15 tablets for patients aged 65 years or older.

Dr. Mark, Dr. Weston, and Dr. Dowdy had no disclosures.

SOURCE: Mark J et al. SGO 2018, Abstract 7. Weston E et al. SGO 2018, Abstract 8.

Pages

Recommended Reading

Avelumab safety compares with other checkpoint inhibitors
MDedge ObGyn
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge ObGyn
Chlamydia infections associated with more than a doubling of ovarian cancer risk
MDedge ObGyn
Same-day discharge for hysterectomy
MDedge ObGyn
VIDEO: Everolimus/letrozole promising for recurrent endometrial cancer
MDedge ObGyn
VIDEO: Pelvic radiation surpasses brachytherapy/chemo for early endometrial cancer
MDedge ObGyn
Oncologist-led BRCA mutation testing and counseling may reduce wait times for women with ovarian cancer
MDedge ObGyn
Combined PARP, checkpoint inhibitor regimens show ovarian cancer activity
MDedge ObGyn
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
MDedge ObGyn
VIDEO: Cervical cancer laparotomy outperforms minimally invasive surgery
MDedge ObGyn